<?xml version="1.0" encoding="UTF-8"?>
<p>Above all, the basic research and results of clinical treatment with tocilizumab and CVL218 based on conventional therapy remind researchers that exploring novel uses of already approved drugs (repurposing) may also be an effective strategy for treating SARS‐CoV‐2‐induced PARS.</p>
